The Modern Data Company and Thoughtworks Form Strategic Alliance to Accelerate Data Mesh Implementations and AI Initiatives
18.7.2023 13:12:00 EEST | Business Wire | Press release
The Modern Data Company, pioneers of the world's first data operating system, DataOS®, is thrilled to announce a strategic partnership with renowned global technology consultancy, Thoughtworks (NASDAQ: TWKS). This groundbreaking collaboration is set to reimagine data operations and accelerate the adoption of Data Products, Data Mesh, and AI initiatives across a wide range of industries.
Harnessing its rich expertise in data strategies, Thoughtworks has led numerous successful data transformation initiatives. The pairing of this experience with the technologically advanced Modern Data Company’s DataOS Platform--designed to streamline creation and management of Data Products, the key ingredients for a Data Mesh implementation--forms the backbone of this partnership. This collaborative alliance is set to unlock the full potential of organizational data, spearhead innovation, and pave the way for successful data modernization initiatives.
“The partnership between Modern and Thoughtworks marks a significant step as we transform how data is implemented and applied across an organization. We're changing the game by moving from traditional tables to a Data Product approach, and this collaboration significantly advances our shared vision. At The Modern Data Company, we firmly believe that the future lies in viewing and treating data as a product. This reimagining enables rapid, comprehensive creation and management of data, accelerating innovation and unlocking its full potential,” said Srujan Akula, CEO, The Modern Data Company. “By pairing Thoughtworks' profound expertise in data strategies with our innovative DataOS platform, we're poised to bring about a transformative shift in how organizations leverage their data.”
DataOS is an integrated platform that simplifies and expedites data development cycles. It equips teams with the comprehensive tools to easily build, manage, deploy, and iterate on their data products, all while ensuring seamless compatibility with the existing data infrastructure. This enables businesses to use their data assets without interruptions, maximizing derived value.
“The Modern Data Company and Thoughtworks have partnered to combine the world’s first data operating system, Modern’s DataOS, and Thoughtworks’ world-class data engineering and AI practices to help you thrive in today’s data-driven economy,” said John Spens, VP Data & AI Service Line, Thoughtworks. “Accelerate insights to drive your business by delivering transparent, trustworthy and accessible data efficiently and well.”
Stay tuned for more updates on this strategic partnership. For more information about The Modern Data Company and Thoughtworks, please visit their websites at https://TheModernDataCompany.com and https://Thoughtworks.com, respectively.
About The Modern Data Company:
The Modern Data Company offers comprehensive data management products. Our flagship product, DataOS®, is a data operating system pioneered to build comprehensive data products and accelerate the adoption of data mesh implementations so that organizations become truly data-driven and AI-ready.
See The Modern Data Company at CDOIQ 2023 in Cambridge, MA. at Booth #29 to learn more about data products and data mesh implementations.
About Thoughtworks
Thoughtworks is a global technology consultancy with more than 12,500 employees in 50 offices across 18 countries. It integrates strategy, design, and software engineering services for clients ranging from global Fortune 500 enterprises to digital natives and digital scaleups in industries like automotive, retail, financial services, healthcare, and the public sector. Founded in 1993, Thoughtworks is headquartered in Chicago.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230718888038/en/
Contact information
Press Contact:
Emanuel Younanzadeh
VP Marketing
The Modern Data Company
emanuel@tmdc.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom